PL404913A1 - Zwiazek 2,3-dihydro-6-nitroimidazo[2,1-b]oksazolowy - Google Patents

Zwiazek 2,3-dihydro-6-nitroimidazo[2,1-b]oksazolowy

Info

Publication number
PL404913A1
PL404913A1 PL404913A PL40491303A PL404913A1 PL 404913 A1 PL404913 A1 PL 404913A1 PL 404913 A PL404913 A PL 404913A PL 40491303 A PL40491303 A PL 40491303A PL 404913 A1 PL404913 A1 PL 404913A1
Authority
PL
Poland
Prior art keywords
oxazole
nitroimidazo
dihydro
compound
mycobacterium tuberculosis
Prior art date
Application number
PL404913A
Other languages
English (en)
Polish (pl)
Inventor
Hidetsugu Tsubouchi
Hirofumi Sasaki
Hideaki Kuroda
Motohiro Itotani
Takeshi Hasegawa
Yoshikazu Haraguchi
Takeshi Kuroda
Takayuki Matsuzaki
Kuninori Tai
Makoto Komatsu
Makoto Matsumoto
Hiroyuki Hashizume
Tatsuo Tomishige
Yuji Seike
Masanori Kawasaki
Takumi Sumida
Shin Miyamura
Original Assignee
Otsuka Pharmaceutical Co.,Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co.,Ltd. filed Critical Otsuka Pharmaceutical Co.,Ltd.
Publication of PL404913A1 publication Critical patent/PL404913A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL404913A 2002-10-11 2003-10-10 Zwiazek 2,3-dihydro-6-nitroimidazo[2,1-b]oksazolowy PL404913A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002298259 2002-10-11

Publications (1)

Publication Number Publication Date
PL404913A1 true PL404913A1 (pl) 2013-09-30

Family

ID=32089299

Family Applications (3)

Application Number Title Priority Date Filing Date
PL404913A PL404913A1 (pl) 2002-10-11 2003-10-10 Zwiazek 2,3-dihydro-6-nitroimidazo[2,1-b]oksazolowy
PL409525A PL409525A1 (pl) 2002-10-11 2003-10-10 Związek 2,3-dihydro-6-nitroimidazo[2,1-b]oksazolowy
PL376157A PL217919B1 (pl) 2002-10-11 2003-10-10 Związek 2,3-dihydro-6-nitroimidazo[2,1-b]oksazolowy, kompozycja go zawierająca oraz zastosowanie

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL409525A PL409525A1 (pl) 2002-10-11 2003-10-10 Związek 2,3-dihydro-6-nitroimidazo[2,1-b]oksazolowy
PL376157A PL217919B1 (pl) 2002-10-11 2003-10-10 Związek 2,3-dihydro-6-nitroimidazo[2,1-b]oksazolowy, kompozycja go zawierająca oraz zastosowanie

Country Status (26)

Country Link
US (1) US7262212B2 (cg-RX-API-DMAC7.html)
EP (2) EP2570418A3 (cg-RX-API-DMAC7.html)
JP (1) JP4186065B2 (cg-RX-API-DMAC7.html)
KR (1) KR100723847B1 (cg-RX-API-DMAC7.html)
CN (4) CN101172981A (cg-RX-API-DMAC7.html)
AR (4) AR041198A1 (cg-RX-API-DMAC7.html)
AU (1) AU2003272979B2 (cg-RX-API-DMAC7.html)
BE (1) BE2014C053I2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0314344B8 (cg-RX-API-DMAC7.html)
CA (1) CA2497569C (cg-RX-API-DMAC7.html)
CY (2) CY1113578T1 (cg-RX-API-DMAC7.html)
DK (1) DK1555267T3 (cg-RX-API-DMAC7.html)
ES (1) ES2400179T3 (cg-RX-API-DMAC7.html)
FR (1) FR14C0066I2 (cg-RX-API-DMAC7.html)
HU (1) HUS1400046I1 (cg-RX-API-DMAC7.html)
LU (1) LU92517I2 (cg-RX-API-DMAC7.html)
MX (1) MXPA05003674A (cg-RX-API-DMAC7.html)
MY (1) MY139244A (cg-RX-API-DMAC7.html)
PL (3) PL404913A1 (cg-RX-API-DMAC7.html)
PT (1) PT1555267E (cg-RX-API-DMAC7.html)
RU (1) RU2326121C3 (cg-RX-API-DMAC7.html)
SI (1) SI1555267T1 (cg-RX-API-DMAC7.html)
TW (1) TWI347946B (cg-RX-API-DMAC7.html)
UA (1) UA83200C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004033463A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200501033B (cg-RX-API-DMAC7.html)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE502928T1 (de) 2000-11-01 2011-04-15 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
KR100655670B1 (ko) * 2002-10-15 2007-02-28 오쓰까 세이야꾸 가부시키가이샤 1-치환된 4-니트로이미다졸 화합물 및 이의 제조 방법
JP4761756B2 (ja) * 2003-10-31 2011-08-31 大塚製薬株式会社 ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物
TWI335331B (en) 2003-10-31 2011-01-01 Otsuka Pharma Co Ltd 2,3-dihydro-6-nitroimidazo [2,1-b] oxazole compound
TWI300409B (en) 2004-02-18 2008-09-01 Otsuka Pharma Co Ltd Method for producing 4-nitroimidazole compound
PT1731518E (pt) 2004-03-31 2014-09-18 Nippon Soda Co Composto amina cíclico e agente de controlo de pragas
JP4787529B2 (ja) * 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
JP4789966B2 (ja) * 2004-04-09 2011-10-12 大塚製薬株式会社 医薬組成物
MX2007016523A (es) * 2005-06-20 2008-03-06 Schering Corp Piperidinas sustituidas ligadas a carbono y derivados de las mismas utiles como antagonistas de hsitamina h3.
CN101222913B (zh) * 2005-07-28 2011-09-21 大塚制药株式会社 包含2，3-二氢-6-硝基咪唑[2，1-b]噁唑衍生物的药物组合物
TW201233389A (en) * 2005-10-05 2012-08-16 Otsuka Pharma Co Ltd Antituberculous therapeutic drugs and kit containing the same
JP5105818B2 (ja) * 2005-10-05 2012-12-26 大塚製薬株式会社 医薬組成物
BRPI0616667B1 (pt) * 2005-10-06 2017-07-18 Nippon Soda Co. , Ltd. Compounds of cyclical amine or salts thereof or non-oxides thereof, and agents for control of fever
TW200800268A (en) * 2005-11-04 2008-01-01 Otsuka Pharma Co Ltd Medicinal composition showing improved drug absorbability
WO2007078335A2 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
JP2009526773A (ja) * 2006-02-13 2009-07-23 ラボラトワール セローノ ソシエテ アノニム 細菌感染症治療のためのスルホンアミド誘導体
JP2007297305A (ja) * 2006-04-28 2007-11-15 Daiso Co Ltd Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法
US8835426B2 (en) * 2007-02-26 2014-09-16 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1
AR070301A1 (es) * 2007-05-08 2010-03-31 Otsuka Pharma Co Ltd Compuesto epoxi y metodo para producir el mismo
ATE554078T1 (de) * 2007-07-26 2012-05-15 Vitae Pharmaceuticals Inc Synthese von 11-beta-hydroxysteroid-dehydrogenase-1-hemmern
WO2009021965A2 (en) * 2007-08-15 2009-02-19 Glaxo Group Limited Substituted quinoline derivatives as h1 receptor antagonists
US20100222349A1 (en) * 2007-10-16 2010-09-02 Glaxo Group Limited Quinoline derivatives used to treat inflammatory and allergic diseases
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
WO2009075835A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceutical, Inc CYCLIC UREA INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
JP5490020B2 (ja) 2008-01-24 2014-05-14 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状カルバゼート及びセミカルバジドインヒビター
JP5734666B2 (ja) * 2008-02-11 2015-06-17 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の１，３−オキサアゼパン−２−オン及び１，３−ジアゼパン−２−オン阻害剤
EP2254872A2 (en) * 2008-02-15 2010-12-01 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
JP5538356B2 (ja) * 2008-03-18 2014-07-02 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤
CA2712613C (en) * 2008-03-26 2017-02-28 Global Alliance For Tb Drug Development Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones
CL2009001058A1 (es) 2008-05-01 2010-09-10 Vitae Pharmaceuticals Inc Compuestos derivados de oxazinas sustituidas, inhibidores de la 11b-hidroxiesteroide deshidrogenasa de tipo-1; composicion farmaceutica; y uso del compuesto para inhibir la actividad de 11b-hsd1, como en el tratamiento de la diabetes, dislipidemia, hipertension, obesidad, cancer, glaucoma, entre otras.
CA2723032A1 (en) * 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8592410B2 (en) 2008-05-01 2013-11-26 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1
AU2009241727B2 (en) 2008-05-01 2013-05-02 Vitae Pharmaceuticals, Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2729998A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5379160B2 (ja) 2008-07-25 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
AU2009283195A1 (en) * 2008-08-18 2010-02-25 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
WO2010143007A1 (en) * 2009-06-10 2010-12-16 Dynamit Nobel Gmbh Explosivstoff-Und Systemtechnik Method for the production of 2-halogeno-4-nitroimidazole
WO2010021409A1 (en) 2008-08-21 2010-02-25 Dynamit Nobel Gmbh Explosivstoff - Und Systemtechnik Methods for the production of 2-halo-4-nitroimidazole and intermediates thereof
CA2744946A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
MA33216B1 (fr) 2009-04-30 2012-04-02 Boehringer Ingelheim Int Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
GEP20156309B (en) * 2009-04-30 2015-07-10 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2440537A1 (en) 2009-06-11 2012-04-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
JP5749263B2 (ja) 2009-07-01 2015-07-15 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
US9198913B2 (en) 2009-07-31 2015-12-01 Global Alliance For Tb Drug Development Nitroimidazooxazines and their uses in anti-tubercular therapy
WO2011014776A1 (en) * 2009-07-31 2011-02-03 Global Alliance For Tb Drug Development Nitroimidazooxazine and nitroimidazooxazole analogues and their uses
KR101746482B1 (ko) * 2009-07-31 2017-06-27 글로벌 알리앙스 포 티비 드럭 디벨롭먼트 니트로이미다조옥사진 및 항결핵 치료요법에서의 이의 용도
WO2011052522A1 (ja) 2009-10-26 2011-05-05 富士フイルムＲｉファーマ株式会社 感染症診断薬
TW201200523A (en) 2010-01-29 2012-01-01 Otsuka Pharma Co Ltd Synthetic intermediate of oxazole compound and method for producing the same
GB201012209D0 (en) * 2010-05-31 2010-09-08 Ge Healthcare Ltd In vivo imaging agent
JP5860042B2 (ja) 2010-06-16 2016-02-16 ヴァイティー ファーマシューティカルズ，インコーポレイテッド 置換５、６及び７員複素環、そのような化合物を含有する医薬及びそれらの使用
JP5813106B2 (ja) 2010-06-25 2015-11-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝障害の処置のための１１−β−ＨＳＤ１のインヒビターとしてのアザスピロヘキサノン
CA2813671A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
EP2697232B1 (en) 2011-04-15 2016-05-18 Otsuka Pharmaceutical Co., Ltd. 6,7-dihydroimidazo[2,1-b][1,3]oxazine bactericides
JP2015006994A (ja) * 2011-10-28 2015-01-15 大正製薬株式会社 ジヒドロイミダゾオキサゾール誘導体
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
FR3000064A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes
US9845330B2 (en) * 2013-10-04 2017-12-19 Council Of Scientific & Industrial Research 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles and a process for the preparation thereof
CN103524492A (zh) * 2013-10-23 2014-01-22 中国药科大学 侧链含硝基咪唑基团取代的喹诺酮类化合物、其制备及用途
AR101704A1 (es) 2014-08-28 2017-01-04 Otsuka Pharma Co Ltd Compuestos heterocíclicos fusionados
JP6467042B2 (ja) * 2014-10-21 2019-02-06 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 抗マイコバクテリア剤としての置換１，２，３−トリアゾール−１−イル−メチル−２，３−ジヒドロ−２−メチル−６−ニトロイミダゾ［２，１−ｂ］オキサゾールとその調製方法
CN105732659B (zh) * 2014-12-12 2019-07-16 上海阳帆医药科技有限公司 硝基咪唑类化合物及其制备方法和在制药中的用途
TW201632533A (zh) 2015-01-29 2016-09-16 南京明德新藥研發股份有限公司 抗肺結核病的硝基咪唑衍生物
WO2016158737A1 (ja) * 2015-03-27 2016-10-06 大塚製薬株式会社 １－（４－ヒドロキシフェニル）－４－（４－トリフルオロメトキシフェノキシ）ピペリジン又はその塩の製造方法
CN106317072B (zh) * 2015-06-17 2020-03-17 盟科医药技术(上海)有限公司 用于分枝杆菌感染治疗的杂环化合物及其应用
WO2017146246A1 (ja) 2016-02-26 2017-08-31 大塚製薬株式会社 ピペリジン誘導体
CN105859628B (zh) * 2016-04-19 2018-08-07 清远职业技术学院 一种抗菌化合物对n咪唑苯甲醛缩邻甲苯胺希夫碱及其制备方法和应用
BR112019001163A2 (pt) * 2016-07-22 2019-04-30 Medshine Discovery Inc. cristal e sal de nitroimidazol e método de fabricação do mesmo
ES2899365T3 (es) * 2017-08-16 2022-03-11 Glaxosmithkline Ip Dev Ltd Compuestos novedosos
WO2019240104A1 (ja) 2018-06-11 2019-12-19 大塚製薬株式会社 デラマニド含有組成物
CN109705022A (zh) * 2018-12-28 2019-05-03 上海彩迩文生化科技有限公司 一种芳香胺中间体的制备方法
CN112300192B (zh) * 2019-08-02 2023-08-11 南京长澳医药科技有限公司 硝基咪唑类化合物及其制备方法和用途
CN110483549B (zh) * 2019-08-30 2021-03-05 沈阳药科大学 一种硝基咪唑吡喃类抗结核药物的制备方法
CN110615800A (zh) * 2019-10-16 2019-12-27 李丽丽 硝基咪唑类化合物及其制备方法和用途
CN112156088B (zh) * 2020-10-30 2021-08-31 健民药业集团股份有限公司 一种化合物在制备结核分枝杆菌抑制剂中的用途
CN113603706A (zh) * 2021-08-04 2021-11-05 深圳市泰力生物医药有限公司 德拉马尼的晶型、含有该晶型的活性药物和药物组合物
EP4563147A1 (en) 2022-07-29 2025-06-04 Otsuka Pharmaceutical Co., Ltd. Delamanid-containing solid dispersion
CN115368252B (zh) * 2022-09-19 2024-01-12 西北农林科技大学 一种4-胺基酚类衍生物及应用
CN116640106B (zh) * 2023-05-11 2024-03-08 郑州大学 一种苯基哌嗪类化合物及其制备方法、应用
CN119059990B (zh) * 2024-11-01 2025-02-07 安徽昊帆生物有限公司 1-氨基甲酸叔丁酯哌嗪的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668127A (en) 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof

Also Published As

Publication number Publication date
TWI347946B (en) 2011-09-01
CA2497569A1 (en) 2004-04-22
PL409525A1 (pl) 2014-11-10
HK1171018A1 (en) 2013-03-15
TW200420568A (en) 2004-10-16
AR041198A1 (es) 2005-05-04
US7262212B2 (en) 2007-08-28
CN100366624C (zh) 2008-02-06
AU2003272979A1 (en) 2004-05-04
MY139244A (en) 2009-09-30
JP2004149527A (ja) 2004-05-27
ES2400179T3 (es) 2013-04-08
BRPI0314344B8 (pt) 2021-05-25
AR089950A2 (es) 2014-10-01
KR100723847B1 (ko) 2007-05-31
RU2005114017A (ru) 2006-01-20
CY2014041I1 (el) 2016-07-27
CY2014041I2 (el) 2016-07-27
HUS1400046I1 (hu) 2017-04-28
ZA200501033B (en) 2006-06-28
AR086485A2 (es) 2013-12-18
CN102532162A (zh) 2012-07-04
AR091771A2 (es) 2015-02-25
CA2497569C (en) 2011-05-24
LU92517I2 (fr) 2014-10-13
CN101255170A (zh) 2008-09-03
BE2014C053I2 (cg-RX-API-DMAC7.html) 2022-08-30
FR14C0066I1 (cg-RX-API-DMAC7.html) 2014-10-17
US20060094767A1 (en) 2006-05-04
UA83200C2 (en) 2008-06-25
AU2003272979B2 (en) 2009-07-23
WO2004033463A1 (ja) 2004-04-22
SI1555267T1 (sl) 2013-05-31
RU2326121C2 (ru) 2008-06-10
CN1705670A (zh) 2005-12-07
CN101172981A (zh) 2008-05-07
PT1555267E (pt) 2013-01-29
BR0314344A (pt) 2005-07-12
HK1085463A1 (zh) 2006-08-25
RU2326121C3 (ru) 2021-09-17
CY1113578T1 (el) 2016-06-22
BRPI0314344B1 (pt) 2019-11-26
MXPA05003674A (es) 2005-06-08
DK1555267T3 (da) 2013-02-11
EP2570418A2 (en) 2013-03-20
FR14C0066I2 (fr) 2015-05-22
EP1555267B1 (en) 2013-01-16
CN102532162B (zh) 2015-05-27
PL376157A1 (en) 2005-12-27
KR20050061473A (ko) 2005-06-22
EP1555267A1 (en) 2005-07-20
JP4186065B2 (ja) 2008-11-26
EP2570418A3 (en) 2013-07-03
PL217919B1 (pl) 2014-09-30
EP1555267A4 (en) 2010-08-18

Similar Documents

Publication Publication Date Title
PL404913A1 (pl) Zwiazek 2,3-dihydro-6-nitroimidazo[2,1-b]oksazolowy
NO996269L (no) Kinolin-indol antimikrobielle midler, samt anvendelse og blandinger derav
ID29076A (id) Kombinasi senyawa aktif fungisida
TR199902400T2 (xx) Fungusit etkinlik g�steren terkiplerin birle�imleri.
NZ599174A (en) Combinations comprising a fungicidal strain and an azolopyrimidin-7-ylamine
MY135333A (en) Modulators of the glucocorticoid receptor
NO20052787D0 (no) N-alkyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
SI1583541T1 (sl) Spojine in postopki za povečanje nevrogeneze
ATE509917T1 (de) Gamma-secretase-inhibitoren
NO20051082L (no) Antimikrobielle kinoloner, deres sammensetninger og anvendelser
MX2010002295A (es) Formas solidas que comprenden n-(5-ter-butil-isoxazol-3-il)-n´-{4- [7-(2-morfolin-4-il-etoxi) imidazo [2,1-b]-[1,3] benzotiazol-2-il] fenil} urea, composiciones de las mismas, y usos de las mismas.
ATE353894T1 (de) Acyloxymethylcarbamat-prodrugs von oxazolidinonen
DE60331849D1 (de) Antibakterielle wirkstoffe
WO2005012320A3 (en) Novel lincomycin derivatives possessing antimicrobial activity
WO2006055070A3 (en) Novel lincomycin derivatives possessing antibacterial activity
SE0302129D0 (sv) Farmaceutiska kompositioner med antibiotisk aktivitet
AR029544A1 (es) Composiciones y metodos para tratar infecciones bacterianas
EA200500353A1 (ru) Производные линкомицина, обладающие антибактериальной активностью
TW200602295A (en) Organic compounds
ECSP066605A (es) Derivados oxazol de tetraciclina
NO331012B1 (no) N-sulfonyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
AU2005273867A1 (en) Benzothienopyridines for use as inhibitors of Eg5 kinesin
EA200500326A1 (ru) Применение ферментированного экстракта проростков пшеницы в качестве противовоспалительного агента
WO2005007665A3 (en) Lincomycin derivatives possessing antibacterial activity
HRP20050611B1 (hr) Kombinacijski lijek